Together, We Can Bring Hope and Support to Families Impacted by Rare Diseases.

Patients

At Zogenix, patients and their families are central to everything we do. We strive to rapidly deliver treatments that address unmet medical needs, in order to change the lives of patients and their communities.

The Pipeline

We are advancing development of therapies for some of the most complex and severe forms of pediatric epilepsy, like Dravet syndrome and Lennox-Gastaut syndrome (LGS).

View All Products

ZX008 – Dravet syndrome

Lead investigational candidate, ZX008 (low-dose fenfluramine) for the treatment of Dravet syndrome

Formulation

Fenfluramine hydrochloride oral solution

Status

Phase 3 trials completed

ZX008 – Lennox-Gastaut syndrome

Investigational product candidate, ZX008 (low-dose fenfluramine) for the treatment of Lennox-Gastaut syndrome (LGS)

Formulation

Fenfluramine hydrochloride oral solution

Status

Global phase 3 trial ongoing

Our Story

Zogenix is committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases.